As the human body ingests substances and medications, it utilizes a variety of metabolism and elimination processes. The second focus in this article will be zero and first-order kinetic elimination, which are clinically useful in achieving a therapeutic level of medication and prognostically assessing toxicity levels and implementing treatment. For simplicity, the following discussion will be specific to a one-compartment model, which views the human body as a homogeneous unit. Lastly, while the vast majority of drugs undergo elimination via first-order kinetics, a firm understanding of both zero and first-order kinetics is crucial in a clinical setting, as there can be fluidity between the two types of elimination with the same specific substance.
Determination and understanding of how a particular substance is eliminated are important when administering medications to achieve a therapeutic level and when assessing a patient who ingested a toxic substance. Specifically, in regards to toxicology, if the ingested substance is unknown to the patient and practitioner, routine blood/plasma testing of the substance and analysis of the decline in concentration will aid in the identification of the ingested substance. For example, if the substance follows a zero-order elimination, the amount eliminated will be dependent on time and not the amount ingested, in contrast to first-order kinetics, in which the amount eliminated will be dependent on the maximum blood/plasma concentration and not of time. Furthermore, once the substance and its properties are understood, proper treatment may be given to a patient that ingested a toxic substance.
To achieve a desired therapeutic level of a medication, a clinician must understand the elimination order and utilize the information in subsequent dosing to maintain the therapeutic concentration over a set period. Misunderstanding of kinetic elimination may lead to patients experiencing toxic symptoms and could lead to other iatrogenic adverse effects up to and including death.
The kidneys are the primary excretory system; whereas, the hepatic system is the main site involved in drug metabolism. Other sites of metabolism include the gastrointestinal tract, pulmonary system, kidneys, and skin. An important concept to understand is any impairment of the described systems may alter how a therapeutic level of medication is achieved and can predispose patients to toxicity symptoms with a dose that would otherwise be well-tolerated in a healthy individual. Both metabolism and excretion are combined to form the rate constant of elimination, which is useful in determining the order of elimination. This equation appears in "Equation No. 2", where "k" represents the rate constant of elimination, and "km" and "ke" represent the rate constant for metabolism and the rate constant for excretion, respectively.
The fundamental difference between zero and first-order kinetics is their elimination rate compared to total plasma concentration. Zero-order kinetics undergo constant elimination regardless of the plasma concentration, following a linear elimination phase as the system becomes saturated. A simple analogy would be an athlete signing an autograph on a picture. Regardless of the total amount of photographs that must be signed, the athlete can only sign one autograph every 15 seconds. The rate-limiting factor of this analogy and zero-order kinetics is time.
First-order kinetics proportionally increases elimination as the plasma concentration increases, following an exponential elimination phase as the system never achieves saturation. Furthermore, when attempting to obtain a therapeutic level of plasma concentration or regarding drug toxicity, one must utilize their knowledge of a particular drug elimination kinetic. To utilize the same analogy, now the entire team can sign the photographs. The more photographs there are to sign, the more athletes can sign. The rate-limiting factor of this analogy and in first-order kinetics is the initial concentration.
In the case of the autographs, if the amount of needed autographed photos exceeds the number of available athletes, the first-order elimination then becomes zero-order. As described above, the system of first-order kinetic elimination can become saturated, which will force a zero-order kinetic model to take place. Importantly, once the concentration falls below a certain level, a first-order kinetic elimination will once again be seen as the system is no longer saturation.
Both zero and first-order kinetics derive from the same equation. As seen in "Equation No. 1 "Kinetic order elimination equation," where delta [drug] represents the change in plasma concentration of the drug divided by time, "n" represents either first or zero-order elimination with 1 or 0, respectively, and "-Kc" represents a constant. For example, when n = 1, the change in drug plasma concentration divided by time is proportional to the amount of drug initially given, showing the rate-limiting factor being the initial concentration. In contrast, when n = 0, [Drug]^0 = equal 1, the change of drug plasma concentration is equal to the constant, -Kc. Thus demonstrating how the rate-limiting factor is time.
The same principles with zero and first-order kinetics are demonstrable on a graph. As seen in "Graph 1: Zero-order kinetics", regardless of the plasma concentration of a substance, the same amount is limited over 2 hours. Thus, the graph demonstrates a linear slope. In comparison to "Graph 2: First-order kinetics," the exponential curve of the graph illustrates how a larger plasma concentration implies a larger amount eliminated in a 2-hour time span.
When administering medications, one must fully understand the mechanism of action and elimination to reduce any unwanted adverse effects. Furthermore, when assessing a patient who may have either intentionally or accidentally ingested a toxic quantity of a substance, knowing that substance's elimination properties will aid treatment and the disease course.
For example, in the case of methanol ingestion, urgent treatment is necessary. Methanol itself results in sedation but is generally nontoxic. The toxicity of methanol is a function of its metabolites. As methanol follows zero-order kinetic elimination, a clinician can understand that the actual danger lies in the time from the ingestion, not the total amount. In contrast to methanol, other specific medications that show zero-order elimination are salicylates, omeprazole, fluoxetine, phenytoin, and cisplatin, which, when ingested at toxic levels, will achieve a higher concentration of the substance within the body over time versus the same amount of the substance that uses first-order elimination.
A firm understanding of the above-described concepts will help reduce the adverse effects of medications on patients and lead the practitioner to choose better treatments for patients experiencing toxicity symptoms.
|||Ф-order kinetics of photoreversible-drug reactions., Maafi M,Maafi W,, International journal of pharmaceutics, 2014 Aug 25 [PubMed PMID: 24857881]|
|||Kinetics and metabolism of fomepizole in healthy humans., McMartin KE,Sebastian CS,Dies D,Jacobsen D,, Clinical toxicology (Philadelphia, Pa.), 2012 Jun [PubMed PMID: 22554311]|
|||Introducing total substrates simplifies theoretical analysis at non-negligible enzyme concentrations: pseudo first-order kinetics and the loss of zero-order ultrasensitivity., Pedersen MG,Bersani AM,, Journal of mathematical biology, 2010 Feb [PubMed PMID: 19333602]|
|||Transdermal drug delivery and cutaneous metabolism., Guy RH,Hadgraft J,Bucks DA,, Xenobiotica; the fate of foreign compounds in biological systems, 1987 Mar [PubMed PMID: 3107225]|
|||Population Pharmacokinetic Analyses for Rezafungin (CD101) Efficacy Using Phase 1 Data., Lakota EA,Ong V,Flanagan S,Rubino CM,, Antimicrobial agents and chemotherapy, 2018 Mar 19 [PubMed PMID: 29555631]|
|||Insights into influencing factor, degradation mechanism and potential toxicity involved in aqueous ozonation of oxcarbazepine (CHEM46939R1)., Wang T,Huang ZX,Miao HF,Ruan WQ,Ji XP,Sun FB,Zhao MX,Ren HY,, Chemosphere, 2018 Feb 9 [PubMed PMID: 29524819]|
|||Severe methanol poisoning with neurological sequelae: implications for diagnosis and management., Holt NR,Nickson CP,, Internal medicine journal, 2018 Mar [PubMed PMID: 29512320]|